74 FR 185 pgs. 49020-49021 - Manufacturer of Controlled Substances; Notice of Application

Type: NOTICEVolume: 74Number: 185Pages: 49020 - 49021
FR document: [FR Doc. E9-23067 Filed 9-24-09; 8:45 am]
Agency: Justice Department
Sub Agency: Drug Enforcement Administration
Official PDF Version:  PDF Version

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 16, 2009, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug Schedule
Cathinone (1235) I
Methcathinone (1237) I
N-Ethylamphetamine (1475) I
N,N-Dimethylamphetamine (1480) I
Aminorex (1585) I
4-Methylaminorex (cis isomer) (1590) I
Gamma-Hydroxybutyric acid (2010) I
Methaqualone (2565) I
Alpha-ethyltryptamine (7249) I
Lysergic acid diethylamide (7315) I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348) I
Marihuana (7360) I
Tetrahydrocannabinols (7370) I
Mescaline (7381) I
3,4,5-Trimethoxyamphetamine (7390) I
4-Bromo-2,5-dimethoxyamphetamine (7391) I
4-Bromo-2,5-dimethoxyphenethylamine (7392) I
4-Methyl-2,5-dimethoxyamphetamine (7395) I
2,5-Dimethoxyamphetamine (7396) I
2,5-Dimethoxy-4-ethylamphetamine (7399) I
3,4-Methylenedioxyamphetamine (7400) I
5-Methoxy-3,4-methylenedioxyamphetamine (7401) I
N-Hydroxy-3,4-methylendioxyamphetamine (7402) I
3,4-Methylendioxy-N-ethylamphetamine (7404) I
3,4-Methylenedioxymethamphetamine (7405) I
4-Methoxyamphetamine (7411) I
Alpha-methyltryptamine (7432) I
Bufotenine (7433) I
Diethyltryptamine (7434) I
Dimethyltryptamine (7435) I
Psilocybin (7437) I
Psilocyn (7438) I
5-Methoxy-N,N-diisopropyltyptamine (7439) I
N-Benzylpiperazine (7493) I
Acetyldihydrocodeine (9051) I
Benzylmorphine (9052) I
Codeine-N-oxide (9053) I
Dihydromorphine (9145) I
Heroin (9200) I
Hydromorphinol (9301) I
Methyldihydromorphine (9304) I
Morphine-N-oxide (9307) I
Normorphine (9313) I
Pholcodine (9314) I
Acetylmethadol (9601) I
Allylprodine (9602) I
Alphacetylmethadol except levo-alphacetylmethadol (9603) I
Alphameprodine (9604) I
Alphamethadol (9605) I
Betacetylmethadol (9607) I
Betameprodine (9608) I
Betamethadol (9609) I
Betaprodine (9611) I
Hydroxypethidine (9627) I
Noracymethadol (9633) I
Norlevorphanol (9634) I
Normethadone (9635) I
Trimeperidine (9646) I
Phenomorphan (9647) I
1-Methyl-4-phenyl-4-propionoxypiperidine (9661) I
Para-Fluorofentanyl (9812) I
3-Methylfentanyl (9813) I
Alpha-Methylfentanyl (9814) I
Acetyl-alpha-methylfentanyl (9815) I
Beta-hydroxyfentanyl (9830) I
Beta-hydroxy-3-methylfentanyl (9831) I
Alpha-Methylthiofentanyl (9832) I
3-Methylthiofentanyl (9833) I
Thiofentanyl (9835) I
Amphetamine (1100) II
Methamphetamine (1105) II
Lisdexamfetamine (1205) II
Phenmetrazine (1631) II
Methylphenidate (1724) II
Amobarbital (2125) II
Pentobarbital (2270) II
Secobarbital (2315) II
Glutethimide (2550) II
Nabilone (7379) II
1-Phenylcyclohexylamine (7460) II
Phencyclidine (7471) II
1-Piperidinocyclohexanecarbonitrile (8603) II
Alphaprodine (9010) II
Cocaine (9041) II
Codeine (9050) II
Dihydrocodeine (9120) II
Oxycodone (9143) II
Hydromorphone (9150) II
Diphenoxylate (9170) II
Benzoylecgonine (9180) II
Ethylmorphine (9190) II
Hydrocodone (9193) II
Levomethorphan (9210) II
Levorphanol (9220) II
Isomethadone (9226) II
Meperidine (9230) II
Meperidine intermediate-A (9232) II
Meperidine intermediate-B (9233) II
Meperidine intermediate-C (9234) II
Methadone (9250) II
Methadone intermediate (9254) II
Dextropropoxyphene, bulk (non-dosage forms) (9273) II
Morphine (9300) II
Thebaine (9333) II
Levo-alphacetylmethadol (9648) II
Oxymorphone (9652) II
Noroxymorphone (9668) II
Racemethorphan (9732) II
Alfentanil (9737) II
Sufentanil (9740) II
Tapentadol (9780) II
Fentanyl (9801) II

The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than November 24, 2009.

Dated: September 17, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E9-23067 Filed 9-24-09; 8:45 am]

BILLING CODE 4410-09-P